$-0.59
(Market cap
$1,964 Mln
Revenue (TTM)
$766 Mln
P/E Ratio
--
P/B Ratio
2.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
46.56
-
EV/EBITDA
168
-
Debt to Equity
0.5
-
Book Value
$6.4
-
EPS
$-2
-
Face value
--
-
Shares outstanding
128,475,440
10 Years Aggregate
CFO
$30.30 Mln
EBITDA
$122.24 Mln
Net Profit
$-233.72 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
NeoGenomics (NEO)
| 30.0 | 7.3 | 70.6 | 199.8 | -4.0 | -19.8 | 5.8 |
|
BSE Sensex
| -7.8 | 1.8 | 0.8 | -4.2 | 5.7 | 8.2 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
NeoGenomics (NEO)
| -28.6 | 1.8 | 75.1 | -72.9 | -36.6 | 84.1 | 132.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
NeoGenomics (NEO)
|
15.3 | 1,964.4 | 766.3 | -51.9 | -6.9 | -6.4 | -- | 2.5 |
| 29.6 | 2,757.6 | 3,367.7 | -1,126.2 | -26.1 | -57.5 | -- | 1.4 | |
| 532.3 | 7,065.1 | 2,595.0 | 275.0 | 14.1 | 30.4 | 26.8 | 8.5 | |
| 2.8 | 393.4 | 22,413.0 | -300.0 | 19.4 | -- | 1.5 | 0.5 | |
| 4.9 | 70.7 | 253.5 | -21.6 | -0.8 | -21 | -- | 0.8 | |
| 16.6 | 470.0 | 323.9 | -84.4 | -18.9 | -7.9 | -- | 0.5 | |
| 1.3 | 985.2 | 587.9 | -72.9 | -6.8 | -5.9 | -- | 0.8 | |
| 23.0 | 3,449.6 | 5,693.5 | 209.6 | 6.0 | 16.2 | 17.4 | 2.7 | |
| 6.7 | 1,195.3 | 2,489.5 | -177.4 | -6.4 | -13.2 | -- | 1.2 | |
| 178.2 | 10,383.6 | 5,486.7 | 378.7 | 9.2 | 16.2 | 27.9 | 4.3 |
Shareholding Pattern
View DetailsAbout NeoGenomics (NEO)
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical... companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida. Read more
-
CEO & Director
Mr. Christopher Michael Smith BSc
-
CEO & Director
Mr. Christopher Michael Smith BSc
-
Headquarters
Fort Myers, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for NeoGenomics (NEO)
What is the current share price of NeoGenomics Inc (NEO) Today?
The share price of NeoGenomics Inc (NEO) is $15.29 (NASDAQ) as of 31-Jul-2026 16:03 EDT. NeoGenomics Inc (NEO) has given a return of -3.96% in the last 3 years.
What is the current PB & PE ratio of NeoGenomics Inc (NEO)?
Since, TTM earnings of NeoGenomics Inc (NEO) is negative, P/E ratio is not available.
The P/B ratio of NeoGenomics Inc (NEO) is 2.50 times as on 31-Jul-2026, a 27 discount to its peers’ median range of 3.44 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.80
|
0.36
|
|
2024
|
-5.30
|
0.46
|
|
2023
|
-4.63
|
0.43
|
|
2022
|
-1.60
|
0.23
|
|
2021
|
-100.62
|
0.76
|
What is the 52 Week High and Low of NeoGenomics Inc (NEO)?
The 52-week high and low of NeoGenomics Inc (NEO) are Rs 16.17 and Rs 4.72 as of 02-Aug-2026.
What is the market cap of NeoGenomics Inc (NEO)?
NeoGenomics Inc (NEO) has a market capitalisation of $ 1,964 Mln as on 31-Jul-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in NeoGenomics Inc (NEO)?
Before investing in NeoGenomics Inc (NEO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.